非小细胞肺癌分子靶向治疗药物的现状及进展

The progress of molecular-targeted therapeutic drugs in non-small cell lung cancer

目前肺癌以高发病率、高死亡率居我国恶性肿瘤病死率的首位，严重威胁着人类的健康，其中非小细胞肺癌（non-small cell lung cancer，NSCLC）约占肺癌的80%～90%。遗憾的是大多数患者就诊时已为晚期，错失了外科手术的机会，故内科治疗成为NSCLC晚期患者的主要治疗方法。近些年来分子靶向治疗药物取得了巨大的进展，为NSCLC晚期患者提供了新的治疗手段。本文将就NSCLC的分子靶向药物治疗作一介绍，希望能对临床上NSCLC晚期患者的个体化治疗有所裨益。

Lung cancer is ranked the first among all malignant neoplastic diseases because of its high morbidity and mortality rate. Thus, lung cancer seriously threatens human health. More than 80%of lung cancer cases are non-small cell lung cancer （NSCLC）. Unfortunately, the majority of NSCLC patients are already at the terminal stage of the disease when they seek medical attention. Such patients miss the optimal opportunity of surgery;thus, medical treatment becomes the main choice for them. Recently, molecular-targeted therapy has made tremendous progress in clinical practice and provides a new potential treatment for patients at the terminal stage. In this review, the authors introduced some molecular-targeted therapeutic drugs to provide benefits for the individualized treatment of patients.